RESULTS AND PUBLICATIONS. All data and results obtained within the CLINICAL TRIAL as well as any derivative works and intelectual/industrial property rights arising therefrom are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issues. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOL. Under the provisions of RD 1090/2015, upon completion of the CLINICAL TRIAL, the SPONSOR shall publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the CLINICAL TRIAL final results, the PRINCIPAL INVESTIGATOR can disseminate any data, discoveries or inventions through journals or scientific publications, making reference at least to the SPONSOR. This shall be conducted according to following criteria: Trials on non-marketed products: during the first year, once authorized and marketed in any country; Trials conducted after product has been marketed, during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination at least forty-five (45) days before it is submitted to a scientific journal and at least twenty (20) days before it is summarized as an abstract. In any case, the PRINCIPAL INVESTIGATOR may only use these data subject to express prior written authorization from the SPONSOR.
RESULTS AND PUBLICATIONS. All of the data, the results of the TRIALS, and all of the work and industrial and intellectual property rights arising from it, belong to the SPONSOR, with the PARTIES being subject to the provisions of the applicable legislation. This circumstance will not prevent the LEAD INVESTIGATOR from using the results in their non-commercial professional research and teaching activities, safeguarding the SPONSOR’s industrial and intellectual property rights and respecting the provisions of the PROTOCOL. In accordance with the provisions of RD 1090/2015, the SPONSOR undertakes to publish the results obtained, whether positive or negative, once the TRIALS have ended. This publication will take place in publicly accessible scientific media, preferably in scientific journals. If the final results of the TRIALS are not submitted for publication by the SPONSOR, the LEAD INVESTIGATOR may, for professional purposes and in scientific journals and publications, make such data, discoveries or inventions known, with, at least, a mention of the SPONSOR, in accordance with the following criteria: Trials with products not on the market: in the first year after their authorization and marketing in any country; Trials performed after marketing: in the year following the end of the TRIALS, unless it compromises publication in a medical journal subject to peer review or contravenes national legislation. The SPONSOR must receive a copy of the text proposed for publication and/or dissemination for review, in accordance with the provisions of the PROTOCOL and, in the event that no indications are made in that respect, at least forty-five (45) days before the despatch date to the scientific journal and, at least, twenty (20) days beforehand in the event that it is a summary. At any event, the LEAD INVESTIGATOR may only use the data with prior, express, written authorization from the SPONSOR. The PARTIES agree that the consideration provided for (i) is, in their experience, a just consideration in relation to the services provided; (ii) is not an incentive for, or in exchange for, past, present or future prescriptions, purchases, recommendations, use, obtaining a preferential formulaic status or dispensations of any of the SPONSOR’s products, or, in any way, conditional or any other similar activity; and (iii) does not involve an impairment to the judgment of the LEAD INVESTIGATOR and the HOSPITAL in relation to advising and caring for each one of the Subjects.
RESULTS AND PUBLICATIONS. 9.1. All of the data, the results of the STUDY, and all of the work and industrial and intellectual property rights arising from it, belong to the SPONSOR, with the PARTIES being subject to the provisions of the applicable legislation. This circumstance will not prevent the LEAD INVESTIGATOR and the FIBHULP from using the results in their non-commercial professional research and teaching activities, safeguarding the SPONSOR’s industrial and intellectual property rights and respecting the provisions of the PROTOCOL. The SPONSOR undertakes to publish the results obtained, whether positive or negative, once the STUDY have ended. This publication will take place in publicly accessible scientific media, preferably in scientific journals If the SPONSOR has not submitted the final results of the STUDY for publication, after having received the final report of the STUDY’S results in the space of 24 months, the PRINCIPAL INVESTIGATOR can disseminate the data, discoveries or inventions through journals or scientific publications with professional purposes, with reference at least to the SPONSOR. In this case, The SPONSOR shall receive for its review a copy of the text proposed for publication and/or dissemination at least forty-five (45) days before it is sent to a scientific journal, and at least twenty (20) days before if it is an abstract. In any case, the PRINCIPAL INVESTIGATOR can only use these data after receiving express written authorisation from the SPONSOR.
RESULTS AND PUBLICATIONS. All TRIAL data and results, as well as resulting studies and patent rights, are property of the SPONSOR, and the Parties are bound to comply with relevant legislation. This does not preclude the PRINCIPAL INVESTIGATOR and the FOUNDATION from using the results in their professional activities. As per provisions of RD 223/2004, once the TRIAL is finished, the SPONSOR is bound to publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the TRIAL final results, the PRINCIPAL INVESTIGATOR can disseminate the data, discoveries or inventions through journals or scientific publications, making reference to the SPONSOR, at least. This shall be conducted according to following criteria: Trials on non-marketed products: during the first year, once authorized and marketed in any country; Trials conducted after product has been marketed, during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination, at least forty-five (45) days before it is sent to a scientific journal and at least twenty (20) days before it is summarized as an abstract. In any case, the PRINCIPAL INVESTIGATOR can only use this data subject to prior written authorization on purpose from the SPONSOR is issued.
RESULTS AND PUBLICATIONS. 6.1. FIBHULP recognises the ownership of the SPONSOR of the data and the results derived from the observational study named in this contract.This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities.
RESULTS AND PUBLICATIONS. 3.1. The Recipient agrees to disclose in detail to UFRRJ all scientific information and data made in the performance of the research with the material (“Results”). Preliminary and/or partial results as well as complete sets of results will be disclosed to UFRRJ independent to any publication. The Results obtained by the recipient with the material shall be communicated in detail to the provider scientist.
RESULTS AND PUBLICATIONS. 6.1 All Results will be owned by UMB. Until UMB publishes the Results pursuant to this Article 6 (but not later than twenty four (24) months after the completion of the Project Work): (a) Sponsor shall treat the unpublished Results as UMB’s Confidential Information; and (b) Sponsor may use the unpublished Results only for internal research purposes. Following publication of any Results, Sponsor may use any such published Results for any purpose (but the restrictions of the preceding sentence shall continue to apply to any unpublished Results until the expiration of the twenty four month period).
RESULTS AND PUBLICATIONS. 6.1.FIBHULPrecognises the ownership of the SPONSOR of the data and the results derived from the observational study named in this contract.This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities.
RESULTS AND PUBLICATIONS. 10.1. All data and results obtained within the CLINICAL TRIAL as well as any derivative works and intelectual/industrial property rights arising therefrom are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issues. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOL.
RESULTS AND PUBLICATIONS. All of the data, the results of the CLINICAL TRIAL, and all of the work and industrial and intellectual property rights arising from it, belong to the SPONSOR, with the PARTIES being subject to the provisions of the applicable legislation.This circumstance will not prevent the LEAD INVESTIGATOR and the FIBHULP from using the results in their non-commercial professional research and teaching activities, safeguarding the SPONSOR’s industrial and intellectual property rights and respecting the provisions of the PROTOCOL. In accordance with the provisions of RD 1090/2015, the SPONSOR undertakes to publish the results obtained, whether positive or negative, once the TRIALS have ended. This publication will take place in publicly accessible scientific media, preferably in scientific journals If the final results of the CLINICAL TRIAL are not submitted for publication by the SPONSOR, the LEAD INVESTIGATOR may, for professional purposes and in scientific journals and publications, make such data, discoveries or inventions known, with, at least, a mention of the SPONSOR, in accordance with the following criteria: Clinic Trials with products not on the market: in the first year after their authorization and marketing in any country; Clinic Trials performed after marketing: in the year following the end of the CLINICAL TRIAL, unless it compromises publication in a medical journal subject to peer review or contravenes national legislation. The SPONSOR must receive a copy of the text proposed for publication and/or dissemination for review, in accordance with the provisions of the PROTOCOL and, in the event that no indications are made in that respect, at least forty-five (45) days before the despatch date to the scientific journal and, at least, twenty (20) days before hand in the event that it is a summary. At any event, the LEAD INVESTIGATOR may only use the data with prior, express, written authorization from the SPONSOR.
